Original GlobalRPh source
- Product / population
- Preserved GlobalRPh source, not a freshly verified product label
- Renal measure
- Use the method specified in the original source
Historical source: not automatically current. Review current official labeling and separately attributed additions before use.
GlobalRPh general renal statement
In using ACCUPRIL, consideration should be given to the fact that another angiotensin-converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease.
Geriatric use: This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function. The recommended initial dosage of ACCUPRIL in elderly patients is 10 mg given once daily followed by titration to the optimal response.
Dosing in Renal Impairment: Kinetic data indicate that the apparent elimination half-life of quinaprilat increases as creatinine clearance decreases. Recommended starting doses, based on clinical and pharmacokinetic data from patients with renal impairment, are as follows:
| Creatinine clearance | Maximum recommended initial dose |
|---|---|
| >60 mL/min | 10 mg |
| 30-60 mL/min | 5 mg |
| 10-30 mL/min | 2.5 mg |
| <10 mL/min | Insufficient data for dosage recommendation |
Source: https://globalrph.com/renal/medications-with-general-renal-dosing-statements/